107 related articles for article (PubMed ID: 35947050)
1. Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis.
Zhang Y; Hao X; Hou K; Hu L; Shang J; He S; Yang C; Huang L; Feng Y
Pharmacogenet Genomics; 2022 Sep; 32(7):257-267. PubMed ID: 35947050
[TBL] [Abstract][Full Text] [Related]
2. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
[TBL] [Abstract][Full Text] [Related]
3. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.
Zhang Y; Hou K; Liu F; Luo X; He S; Hu L; Yang C; Huang L; Feng Y
Mycoses; 2021 Aug; 64(8):860-873. PubMed ID: 33896064
[TBL] [Abstract][Full Text] [Related]
4. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.
Imamura CK; Furihata K; Okamoto S; Tanigawara Y
J Clin Pharmacol; 2016 Apr; 56(4):408-13. PubMed ID: 26239045
[TBL] [Abstract][Full Text] [Related]
5. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
Rossow KM; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33234666
[TBL] [Abstract][Full Text] [Related]
9. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese.
He L; Chen S; Li J; Xie X; Huang L; Kuang Y; Xu K; Huang W; Zhao Y; Yang G; Guo C
Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1659-1663. PubMed ID: 32469422
[TBL] [Abstract][Full Text] [Related]
10. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
Kitazono T; Ikeda Y; Nishikawa M; Yoshiba S; Abe K; Ogawa A
J Thromb Thrombolysis; 2018 Nov; 46(4):488-495. PubMed ID: 30074128
[TBL] [Abstract][Full Text] [Related]
11. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
12. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
Yamada T; Mino Y; Naito T; Kawakami J
J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
[TBL] [Abstract][Full Text] [Related]
13. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
Wang T; Zhu H; Sun J; Cheng X; Xie J; Dong H; Chen L; Wang X; Xing J; Dong Y
Int J Antimicrob Agents; 2014 Nov; 44(5):436-42. PubMed ID: 25239277
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.
Tian X; Zhang C; Qin Z; Wang D; Yang J; Zhang X
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0020721. PubMed ID: 34152823
[TBL] [Abstract][Full Text] [Related]
16. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
[TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients.
Bråten LS; Haslemo T; Jukic MM; Ingelman-Sundberg M; Molden E; Kringen MK
Neuropsychopharmacology; 2020 Feb; 45(3):570-576. PubMed ID: 31649299
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.
Kim SH; Lee DG; Kwon JC; Lee HJ; Cho SY; Park C; Kwon EY; Park SH; Choi SM; Choi JH; Yoo JH
Infect Chemother; 2013 Dec; 45(4):406-14. PubMed ID: 24475354
[TBL] [Abstract][Full Text] [Related]
20. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]